Comparison of patients based on treatment strategy (n = 327)*
| . | Lugano I/II . | Lugano IV . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Surgery/CTx, no. (%; n = 163) . | CTx, no. (%; n = 87) . | P . | Surgery/CTx, no. (%; n = 25) . | CTx, no. (%; n = 52) . | P . | |||||
| Age, y | ||||||||||
| ≤ 60 | 109 | (66.9) | 49 | (56.3) | .130 | 13 | (52.0) | 25 | (48.1) | .810 |
| > 60 | 54 | (33.1) | 38 | (43.7) | 12 | (48.0) | 27 | (51.9) | ||
| Performance status | ||||||||||
| ECOG 0/1 | 146 | (89.6) | 79 | (90.8) | .828 | 18 | (72.0) | 33 | (63.5) | .608 |
| ECOG ≥ 2 | 17 | (10.4) | 8 | (9.2) | 7 | (28.0) | 19 | (36.5) | ||
| Lugano stage | ||||||||||
| I | 49 | (30.1) | 20 | (23.0) | .051 | |||||
| II-1 | 70 | (42.9) | 30 | (34.5) | ||||||
| II-2 | 35 | (21.5) | 33 | (37.9) | ||||||
| II-E | 9 | (5.5) | 4 | (4.6) | ||||||
| IPI | ||||||||||
| Low | 134 | (83.2) | 57 | (65.5) | .006 | 1 | (4.0) | 4 | (7.7) | .239 |
| Low to intermediate | 20 | (12.4) | 21 | (24.1) | 6 | (24.0) | 5 | (9.6) | ||
| High to intermediate | 7 | (4.3) | 9 | (10.3) | 12 | (48.0) | 22 | (42.3) | ||
| High | 0 | (0.0) | 0 | (0.0) | 6 | (24.0) | 21 | (40.4) | ||
| Missing | 2 | |||||||||
| Primary mass size | ||||||||||
| Bulky | 45 | 4 | < .001 | 13 | 8 | .002 | ||||
| Nonbulky | 118 | 83 | 12 | 44 | ||||||
| Reason for surgery | ||||||||||
| Mass resection | 98 | (60.1) | 14 | (56.0) | ||||||
| Obstruction | 51 | (31.3) | 8 | (32.0) | ||||||
| Bleeding | 7 | (4.3) | 1 | (4.0) | ||||||
| Perforation | 7 | (4.3) | 2 | (8.0) | ||||||
| Relapse/progression | 4 | (4.6) | ||||||||
| Perforation after CTx | 4 | (4.6) | 2 | (3.8) | ||||||
| Other complications after CTx | 4 | (4.6) | 1 | (1.9) | ||||||
| Chemotherapy regimen | ||||||||||
| CHOP | 69 | (42.3) | 45 | (51.7) | 0.243 | 5 | (20.0) | 15 | (28.8) | .695 |
| R-CHOP | 87 | (53.4) | 36 | (41.4) | 17 | (68.0) | 33 | (63.5) | ||
| Others | 7 | (4.3) | 6 | (6.9) | 3 | (12.0) | 4 | (7.7) | ||
| Radiotherapy | ||||||||||
| Done | 4 | (2.5) | 12 | (13.8) | .001 | 3 | (12.0) | 7 | (13.5) | > .99 |
| Not done | 159 | (97.5) | 75 | (86.2) | 22 | (88.0) | 45 | (86.5) | ||
| Response | ||||||||||
| CR | 139 | (85.3) | 56 | (64.4) | < .001 | 13 | (52.0) | 24 | (46.2) | .971 |
| PR | 2 | (1.2) | 13 | (14.9) | 5 | (20.0) | 13 | (25.0) | ||
| SD | 2 | (1.2) | 4 | (4.6) | 1 | (4.0) | 2 | (3.8) | ||
| PD | 8 | (4.9) | 9 | (10.3) | 3 | (12.0) | 8 | (15.4) | ||
| NE | 12 | (7.4) | 5 | (5.7) | 3 | (12.0) | 5 | (9.6) | ||
| Relapse/progression | ||||||||||
| Local | 14 | (8.6) | 24 | (27.6) | < .001 | 5 | (20.0) | 6 | (11.5) | .454 |
| Systemic | 11 | (6.7) | 8 | (9.2) | 5 | (20.0) | 16 | (30.8) | ||
| None | 138 | (84.7) | 55 | (63.2) | 15 | (60.0) | 30 | (57.7) | ||
| Survival | ||||||||||
| Alive | 143 | (87.7) | 49 | (56.3) | < .001 | 16 | (64.0) | 23 | (44.2) | .409 |
| Unknown† | 8 | (4.9) | 7 | (8.0) | 1 | (4.0) | 4 | (7.7) | ||
| Dead | 12 | (7.4) | 31 | (35.6) | 8 | (32.0) | 25 | (48.1) | ||
| 3-y PFS | 82% | 52% | < .001 | 52% | 34% | .518 | ||||
| 3-y OS | 91% | 62% | < .001 | 58% | 44% | .303 | ||||
| . | Lugano I/II . | Lugano IV . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Surgery/CTx, no. (%; n = 163) . | CTx, no. (%; n = 87) . | P . | Surgery/CTx, no. (%; n = 25) . | CTx, no. (%; n = 52) . | P . | |||||
| Age, y | ||||||||||
| ≤ 60 | 109 | (66.9) | 49 | (56.3) | .130 | 13 | (52.0) | 25 | (48.1) | .810 |
| > 60 | 54 | (33.1) | 38 | (43.7) | 12 | (48.0) | 27 | (51.9) | ||
| Performance status | ||||||||||
| ECOG 0/1 | 146 | (89.6) | 79 | (90.8) | .828 | 18 | (72.0) | 33 | (63.5) | .608 |
| ECOG ≥ 2 | 17 | (10.4) | 8 | (9.2) | 7 | (28.0) | 19 | (36.5) | ||
| Lugano stage | ||||||||||
| I | 49 | (30.1) | 20 | (23.0) | .051 | |||||
| II-1 | 70 | (42.9) | 30 | (34.5) | ||||||
| II-2 | 35 | (21.5) | 33 | (37.9) | ||||||
| II-E | 9 | (5.5) | 4 | (4.6) | ||||||
| IPI | ||||||||||
| Low | 134 | (83.2) | 57 | (65.5) | .006 | 1 | (4.0) | 4 | (7.7) | .239 |
| Low to intermediate | 20 | (12.4) | 21 | (24.1) | 6 | (24.0) | 5 | (9.6) | ||
| High to intermediate | 7 | (4.3) | 9 | (10.3) | 12 | (48.0) | 22 | (42.3) | ||
| High | 0 | (0.0) | 0 | (0.0) | 6 | (24.0) | 21 | (40.4) | ||
| Missing | 2 | |||||||||
| Primary mass size | ||||||||||
| Bulky | 45 | 4 | < .001 | 13 | 8 | .002 | ||||
| Nonbulky | 118 | 83 | 12 | 44 | ||||||
| Reason for surgery | ||||||||||
| Mass resection | 98 | (60.1) | 14 | (56.0) | ||||||
| Obstruction | 51 | (31.3) | 8 | (32.0) | ||||||
| Bleeding | 7 | (4.3) | 1 | (4.0) | ||||||
| Perforation | 7 | (4.3) | 2 | (8.0) | ||||||
| Relapse/progression | 4 | (4.6) | ||||||||
| Perforation after CTx | 4 | (4.6) | 2 | (3.8) | ||||||
| Other complications after CTx | 4 | (4.6) | 1 | (1.9) | ||||||
| Chemotherapy regimen | ||||||||||
| CHOP | 69 | (42.3) | 45 | (51.7) | 0.243 | 5 | (20.0) | 15 | (28.8) | .695 |
| R-CHOP | 87 | (53.4) | 36 | (41.4) | 17 | (68.0) | 33 | (63.5) | ||
| Others | 7 | (4.3) | 6 | (6.9) | 3 | (12.0) | 4 | (7.7) | ||
| Radiotherapy | ||||||||||
| Done | 4 | (2.5) | 12 | (13.8) | .001 | 3 | (12.0) | 7 | (13.5) | > .99 |
| Not done | 159 | (97.5) | 75 | (86.2) | 22 | (88.0) | 45 | (86.5) | ||
| Response | ||||||||||
| CR | 139 | (85.3) | 56 | (64.4) | < .001 | 13 | (52.0) | 24 | (46.2) | .971 |
| PR | 2 | (1.2) | 13 | (14.9) | 5 | (20.0) | 13 | (25.0) | ||
| SD | 2 | (1.2) | 4 | (4.6) | 1 | (4.0) | 2 | (3.8) | ||
| PD | 8 | (4.9) | 9 | (10.3) | 3 | (12.0) | 8 | (15.4) | ||
| NE | 12 | (7.4) | 5 | (5.7) | 3 | (12.0) | 5 | (9.6) | ||
| Relapse/progression | ||||||||||
| Local | 14 | (8.6) | 24 | (27.6) | < .001 | 5 | (20.0) | 6 | (11.5) | .454 |
| Systemic | 11 | (6.7) | 8 | (9.2) | 5 | (20.0) | 16 | (30.8) | ||
| None | 138 | (84.7) | 55 | (63.2) | 15 | (60.0) | 30 | (57.7) | ||
| Survival | ||||||||||
| Alive | 143 | (87.7) | 49 | (56.3) | < .001 | 16 | (64.0) | 23 | (44.2) | .409 |
| Unknown† | 8 | (4.9) | 7 | (8.0) | 1 | (4.0) | 4 | (7.7) | ||
| Dead | 12 | (7.4) | 31 | (35.6) | 8 | (32.0) | 25 | (48.1) | ||
| 3-y PFS | 82% | 52% | < .001 | 52% | 34% | .518 | ||||
| 3-y OS | 91% | 62% | < .001 | 58% | 44% | .303 | ||||
CTx indicates chemotherapy; PR, partial response; SD, stable disease; PD, progressive disease; and NE, not evaluable.
Among 345 patients, 12 patients had surgery only and 6 patients received no treatment.
The survival status was unknown because of follow-up loss. These patients were censored during the Kaplan-Meier survival analysis.